Key Highlights
- Q2 net revenue reached a record $183.6 million, marking a 16% year-over-year increase
- Active patient count across all TTFields therapies climbed 18% to 5,128 globally
- Company achieved positive adjusted EBITDA of $10.8 million compared to a $10 million deficit in the prior year
- 2026 full-year revenue forecast upgraded to $710M–$725M
- Optune Pax secured CE Mark clearance for locally advanced pancreatic cancer across Europe
Shares of NovoCure (NVCR) experienced a dramatic 28.39% surge following the company’s announcement of record-setting quarterly results and an enhanced full-year financial outlook that exceeded investor expectations.
The medical device company delivered Q2 net revenue of $183.6 million, representing a 16% improvement over the comparable quarter last year. This performance not only surpassed analyst projections but also established a new high-water mark for quarterly revenue.
The global patient base utilizing TTFields therapy expanded by 18% year over year, reaching 5,128 active patients. Optune Gio continues to lead the portfolio with 4,636 active patients, while Optune Lua demonstrated robust momentum with 51% growth, bringing its patient count to 207.
For Optune Pax, the pancreatic cancer treatment introduced in U.S. markets earlier this year, the company recorded 418 prescriptions during the second quarter. By the end of June, 285 American patients were actively receiving treatment.
Profitability metrics showed notable improvement with gross margin expanding to 78% from 74% in the year-ago period. This enhancement was partially driven by a $5 million tariff reimbursement and reduced production expenses. Company leadership anticipates margins will stabilize in the mid-70% range throughout the remainder of the year.
The adjusted EBITDA metric flipped to positive territory at $10.8 million versus a $10 million deficit in Q2 2025, representing a significant operational milestone. Despite this progress, the company still reported a GAAP net loss of $15.7 million, though substantially improved from the $40 million loss recorded a year earlier.
Updated Financial Projections
Company executives elevated their full-year 2026 revenue projection to a range of $710 million–$725 million, representing an increase from the previous forecast of $690 million–$710 million. This revised outlook suggests annual growth between 8% and 11%.
The adjusted EBITDA forecast also received an upgrade, shifting from an anticipated loss of up to $15 million to a new range spanning breakeven to a positive $15 million.
NovoCure concluded the quarter holding $440.6 million in cash and short-term investments, providing sufficient financial flexibility to fund commercial expansion efforts and clinical trials without requiring near-term capital raises.
International Growth and Clinical Progress
Optune Pax obtained CE Mark authorization for locally advanced pancreatic cancer throughout Europe. Germany is anticipated to serve as the initial European launch territory.
Approximately half of U.S. physicians who have prescribed Optune Pax have written just a single prescription to date. Converting these initial prescribers into regular users represents a significant commercial priority that management addressed during the earnings discussion.
Optune Lua, designed for malignant pleural mesothelioma patients, enrolled 64 patients in Japan after receiving national reimbursement approval in March. However, the requirement for individual hospital contracting continues to present obstacles to wider market penetration.
Research and development expenditures decreased 8% year over year to $51 million as the organization reduced clinical trial expenses. NovoCure is also restructuring its LUNAR-2 Phase III study to achieve approximately $90 million in cost savings through reduced sample sizes and site optimization.
The FDA is anticipated to render a regulatory decision during Q4 2026 regarding Optune Maia for brain metastases originating from non-small cell lung cancer. The NCCN has previously included Optune Maia as a Category 2A treatment recommendation for patients with limited brain metastases.
Patient recruitment for the Phase 3 KEYNOTE D58 glioblastoma study is projected to reach completion before the close of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
